Dr. P. M. Stone, MD
Critical Care Medicine (Critical Care Medicine (Internal Medicine) Physician)
At a glance
- In the NPI registry since
- 2006
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Critical Care Medicine (Internal Medicine) Physician primary
OR license MD22527 -
Internal Medicine Physician
OR license MD22527
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Medicare patients and services
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 34 | 19 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Payments from drug and device companies
In 2025, 1 companies reported 8 payments worth $1,647 in total to this clinician.
| Boehringer Ingelheim Pharmaceuticals, Inc. | $1,647 |
|---|
| Travel and Lodging | $1,233 |
|---|---|
| Food and Beverage | $414 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Feb 18, 2025 | Travel and Lodging travel to DFW Airport, TX · in-kind | $732 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Apr 15, 2025 | Travel and Lodging travel to DFW Airport, TX · in-kind | $501 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 2 companies. The companies reported $185,136 in research payments for these studies, mostly to the institutions running them.
- A Study of mRNA-1345 Following a Primary Dose of a Licensed Protein Subunit Respiratory Syncytial Virus (RSV) Vaccine in Adult Participants ≥60 Years of Age
ModernaTX, Inc. · Completed · NCT07117487 - Post marketing commitment study to assess clinical efficacy & safety of current JN.1-based formulation with focus on lower-risk adults (50-64 years) to inform benefit-risk profile (PMC2)
ModernaTX, Inc. - A randomized, double-blind, placebo-controlled, multicenter, dose range finding study, to evaluate efficacy, safety and pharmacodynamics of QCZ484 in mild to moderate hypertensive patients
Novartis Pharmaceuticals Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.